Nuveen’s Sagimet Biosciences SGMT Stock Holding History

Nuveen’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-91,655	Closed	-$497K	–	3406
2024 Q1	$497K	Buy	+91,655	New	+$658K	﹤0.01%	2977

Other funds holding SGMT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Nuveen's SGMT Position: Q2 2024 in Review

Nuveen sold out of Sagimet Biosciences (SGMT) in Q2 2024, closing a stake of 91,655 shares — an estimated $497K sold.

Nuveen first reported a position in SGMT in Q1 2024 and held it in 1 quarter. The position peaked at $497K in Q1 2024. 82 funds tracked by Wall St. Rank hold SGMT as of Q2 2024.

Nuveen reported no remaining Sagimet Biosciences position as of Q2 2024 after selling out during the quarter.
Nuveen sold 91,655 Sagimet Biosciences shares in Q2 2024, an estimated $497K.
Nuveen first reported a position in Sagimet Biosciences in Q1 2024 and held it in 1 quarter.
Nuveen's Sagimet Biosciences position peaked at $497K in Q1 2024.
82 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.